CDK6，MLL 驱动白血病的新靶点。

CDK6, a new target in MLL-driven leukemia.

机构信息

ALBERT EINSTEIN COLLEGE OF MEDICINE.

出版信息

Blood. 2014 Jul 3;124(1):5-6. doi: 10.1182/blood-2014-05-572917.

DOI:10.1182/blood-2014-05-572917

Abstract

In this issue of Blood, Placke et al identify the cell-cycle regulator CDK6 as a promising new target in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) and show that its downregulation or pharmacological inhibition leads to growth inhibition and differentiation of MLL-driven leukemic cells.

摘要

在本期《Blood》中，Placke 等人确定细胞周期调节剂 CDK6 是混合谱系白血病（MLL）重排急性髓系白血病（AML）中有前途的新靶点，并表明其下调或药理学抑制可导致 MLL 驱动的白血病细胞的生长抑制和分化。